Honeywell International was targeted by an antitrust complaint from Arkema SA, which alleges the US company prevents fair competition for the only car-coolant chemical that currently meets new European Union standards on greenhouse-gas emissions.
Arkema filed the complaint with the EU’s antitrust authority seeking a “fair, reasonable and non-discriminatory license to Honeywell’s patents” for 1234yf, a refrigerant used in car air-conditioning systems, according to a statement on Friday. Honeywell’s practices harm consumers, car makers and the environment “as the entire car industry is moving to worldwide deployment of 1234yf.”
Honeywell has already been the subject of a stalled EU probe into the refrigerant. Three years ago, the European Commission told Honeywell and Chemours, then owned by DuPont, that they might have unfairly limited supplies of the chemical. Arkema had filed a complaint in that investigation that it says it has now withdrawn.
Honeywell said the new complaint is “without merit” and appears to restate issues regulators decided not to pursue several years ago. The company “remains convinced that it acts in full compliance with EU competition rules.” It has invested nearly $1 billion to bring the coolant to market, it said in an emailed statement.
Full Content: Environmental Leader
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Doug Gurr Appointed Interim Chairman of UK’s Competition Authority
Jan 22, 2025 by
CPI
LinkedIn Faces Lawsuit Over Alleged Misuse of Customer Data for AI Training
Jan 22, 2025 by
Amanda Adams
Johns Hopkins and Caltech Settle for $35.3M in College Price-Fixing Lawsuit
Jan 22, 2025 by
CPI
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan